Virtual Library

Start Your Search

F. Li

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      6P - Mechanisms of regulating PD-L1 expression in non-small cell lung cancer during EMT process (ID 226)

      12:30 - 13:00  |  Presenting Author(s): F. Li

      • Abstract

      Non-small cell lung cancer (NSCLC) is one of the most severe malignant tumors in the world. Recent studies have reported the important role of PD-L1 in immune escape of tumor microenvironment.

      In this study, we explored the molecular mechanisms in regulating the PD-L1 expression during the epithelial-to-mesenchymal transition (EMT) process treated with transforming growth factor β-1 (TGFβ-1) and -2 (FGF-2) in NSCLC. The phenotypic alteration of EMT was evaluated by wound healing assay and western blot. And the protein expression was evaluated by Western Blot and Flow Cytometry Analysis. Furthermore, the expression of PD-L1 was increased significantly treated with Gefitinib in tumor xenograft model.

      The results showed that EMT promoted the expression of PD-L1 remarkably in A549 cell line while have no obvious influence on H1650 and H1975 cell lines. Furthermore, AKT pathway inhibitor Ly294002, Erk pathway inhibitor PD98059 and TAK1 pathway inhibitor 5Z-7 inhibited the expression of PD-L1 in A549 and H1650, but not H1975 in EMT process. Besides, our study indicated that AKT, Erk and TAK1 pathways regulated the expression of PD-L1 by mediating transportation of the transcription factor Stat3 and the subunit p65 of NF-κB from cytoplasm to nucleus.

      Take together, our study supports the role of ERK, AKT and TAK1 in mediating the expression of PD-L1 during EMT process and represents a promising strategy for treatment NSCLC in clinic.

      Clinical trial identification:

      Legal entity responsible for the study:
      Peking University Third Hospital

      Has not received any funding

      All authors have declared no conflicts of interest.